Otis Gets His Wag Back

SAN DIEGO, Oct. 9, 2014 /PRNewswire/ -- Otis, the golden retriever, was in his golden years when bone cancer pain threatened to shorten his life.  As a participant in a clinical trial aimed at pet dogs, he was given a single treatment with a pain therapy called SP-SAP that was developed by a local company, Advanced Targeting Systems (ATS).

The story of Otis' relief from cancer pain is well documented in a video accessible at www.ATSbio.com/vet.  "Otis Gets His Wag Back" shows Otis before treatment and after.  It is clear from Otis' body language and gait there is change for the better, while the tumor has doubled in size.

Bone cancer at advanced stages often leads to animals being euthanized for pain-related issues.  There are better options.  Pain shouldn't be a life-threatening disease for your pet.  SP-SAP prevents chronic pain signals from reaching the brain.  The pet's brain no longer knows it is in pain from the cancer, but can still feel normal acute pain that can be treated with traditional pain care.

A study sponsored by ATS has promising results that were published in the November 2013 issue of the journal Anesthesiology.  Pet dogs receiving SP-SAP displayed significantly less pain than dogs receiving traditional pain care, with no visible side effects and an improved quality of life.

With the hope of translating these results to humans, a clinical trial testing SP-SAP on terminal cancer patients has begun.  Early results are promising, but additional patients are needed.  See http://clinicaltrials.gov/show/NCT02036281 for more information.

Benefits of SP-SAP:

• Permanent relief from cancer pain
• Single injectable dose
• Successfully tested in dogs
• In human clinical trials

About Advanced Targeting Systems, Inc.:
A San Diego-based biotechnology company, ATS is the pioneer in the use of targeted toxins to eliminate specific cells through a powerful technique called Molecular Neurosurgery. Dr. Douglas Lappi, leading expert in the production and use of targeted toxins, and his team at ATS have been developing and selling reagents to the research community for over 20 years.  This targeting technology has a broad spectrum of clinical applications, such as pain, cancer, autoimmune disorders and infectious diseases. ATS is actively seeking a partner to help bring SP-SAP to the veterinary market.

Media contact:
Brian Russell, Vice President of Business Development
Email

Video - http://youtu.be/y7zzr2Sj1RM
Photo - http://photos.prnewswire.com/prnh/20141008/151156

SOURCE Advanced Targeting Systems, Inc.